MVA-BN was approved by the European Medicines Agency (EMA) today for use against Mpox and smallpox in adolescents 12-17 years of age. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children. Dr. Diemert and the GW VRU team are proud to have contributed critical clinical research needed to get this vaccine approved for this vital vulnerable population.
The Mpox Vaccine, MVA-BN, Receives Approval for Use in Adolescents 12 - 17 years of age
Latest News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on theā¦
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: